drugset / Trial / NCT05166577
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma
Timeline
- Start
- 2021-10-08
- Primary completion
- 2024-10-30
- Completion
- 2025-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nanatinostat | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Valganciclovir | Small molecule | 900 mg | Oral |